Profile - To The Moon

firefirefire

enjoy while the going is good..

Posts · 923Posts · 923
Following · 0Following · 0
Followers · 0Followers · 0

- firefirefirefirefirefire
  ·11-03
  Good job! 👍
  Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy
  $Terns Pharmaceuticals(TERN)$ stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel...
  Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy
  299 Comment
  3
  Share
  Report
- firefirefirefirefirefire
  ·02-21
  Hmm.. how I wish this can be consistent in days to come..
  1.88K Comment
  2
  Share
  Report
- firefirefirefirefirefire
  ·02-21
  $NVDA 20250404 136.0 CALL$ good job
  1.24K Comment
  1
  Share
  Report
- firefirefirefirefirefire
  ·02-21
  $NVIDIA(NVDA)$ not too shabby
  1.85K Comment
  2
  Share
  Report
- firefirefirefirefirefire
  ·02-21
  $NDXP 20250220 21930.0 PUT$ not too shabby...
  2.94K 1
  3
  Share
  Report
- firefirefirefirefirefire
  ·02-05
  $NDXP 20250204 21680.0 CALL$ be brave..
  2.81K 4
  6
  Share
  Report
- firefirefirefirefirefire
  ·02-05
  $NDXP 20250204 21580.0 CALL$ not too shabby
  3.31K 1
  4
  Share
  Report
- firefirefirefirefirefire
  ·02-01
  $NDXP 20250131 21850.0 CALL$
  2.76K 1
  3
  Share
  Report
- firefirefirefirefirefire
  ·01-30
  $NDXP 20250129 21580.0 CALL$
  3.14K 1
  3
  Share
  Report
- firefirefirefirefirefire
  ·01-30
  $NDXP 20250129 21580.0 CALL$ collected Lasser from the north side but still is a good shot..
  2.75K 1
  2
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3570742778586711","uuid":"3570742778586711","gmtCreate":1607649655540,"gmtModify":1660529765576,"name":"firefirefire","pinyin":"firefirefire","introduction":"","introductionEn":"","signature":"enjoy while the going is good..","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","hatId":"ca_profile_frame_ugQHMi","hatName":"LV7 头像框","vip":1,"status":2,"fanSize":224,"headSize":475,"tweetSize":923,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":4,"name":"文化虎","nameTw":"文化虎","represent":"学有所成","factor":"发布30条非转发主帖,其中3条优质帖","iconColor":"8867FB","bgColor":"BDC5FF"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":496281679135240,"gmtCreate":1762184942238,"gmtModify":1762184945955,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"title":"","htmlText":"Good job! 👍&nbsp;","listText":"Good job! 👍&nbsp;","text":"Good job! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496281679135240","repostId":"1116417566","repostType":4,"repost":{"id":"1116417566","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1762184400,"share":"https://ttm.financial/m/news/1116417566?lang=&edition=fundamental","pubTime":"2025-11-03 23:40","market":"us","language":"en","title":"Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1116417566","media":"Tiger Newspress","summary":"$Terns Pharmaceuticals(TERN)$ stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/TERN\">Terns Pharmaceuticals</a> stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0475f80f159f6ccffb354578fe3cdfb0\" tg-width=\"539\" tg-height=\"133\"/></p><p style=\"text-align: start;\">The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.</p><p style=\"text-align: start;\">The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.</p><p style=\"text-align: start;\">&#34;The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,&#34; said Amy Burroughs, chief executive officer of Terns.</p><p style=\"text-align: start;\">The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.</p><p style=\"text-align: start;\">The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).</p><p style=\"text-align: start;\">The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Stock Soars on Promising Data for CML Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-11-03 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/TERN\">Terns Pharmaceuticals</a> stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0475f80f159f6ccffb354578fe3cdfb0\" tg-width=\"539\" tg-height=\"133\"/></p><p style=\"text-align: start;\">The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.</p><p style=\"text-align: start;\">The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.</p><p style=\"text-align: start;\">&#34;The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,&#34; said Amy Burroughs, chief executive officer of Terns.</p><p style=\"text-align: start;\">The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.</p><p style=\"text-align: start;\">The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).</p><p style=\"text-align: start;\">The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116417566","content_text":"Terns Pharmaceuticals stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.\"The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,\" said Amy Burroughs, chief executive officer of Terns.The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.","news_type":1,"symbols_score_info":{"TERN":2}},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":405879610086024,"gmtCreate":1740119479856,"gmtModify":1740119483727,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"Hmm.. how I wish this can be consistent in days to come..","listText":"Hmm.. how I wish this can be consistent in days to come..","text":"Hmm.. how I wish this can be consistent in days to come..","images":[{"img":"https://community-static.tradeup.com/news/fdc1b3d44efa35801e216328f4194e81","width":"960","height":"1567"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/405879610086024","isVote":1,"tweetType":1,"viewCount":1876,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":405737002168384,"gmtCreate":1740084482871,"gmtModify":1740084486355,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NVDA 20250404 136.0 CALL\">$NVDA 20250404 136.0 CALL$ </a> good job","listText":"<a href=\"https://ttm.financial/OPT/NVDA 20250404 136.0 CALL\">$NVDA 20250404 136.0 CALL$ </a> good job","text":"$NVDA 20250404 136.0 CALL$ good job","images":[{"img":"https://community-static.tradeup.com/news/8223f3d65af70464edd3ef22179b507a","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/405737002168384","isVote":1,"tweetType":1,"viewCount":1237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":405735991939264,"gmtCreate":1740084444230,"gmtModify":1740084448627,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$ </a> not too shabby","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$ </a> not too shabby","text":"$NVIDIA(NVDA)$ not too shabby","images":[{"img":"https://community-static.tradeup.com/news/5808ff369ecaba01236dd2672fc8a964","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/405735991939264","isVote":1,"tweetType":1,"viewCount":1846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":405735852032120,"gmtCreate":1740084404692,"gmtModify":1740469377111,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250220 21930.0 PUT\">$NDXP 20250220 21930.0 PUT$ </a> not too shabby...","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250220 21930.0 PUT\">$NDXP 20250220 21930.0 PUT$ </a> not too shabby...","text":"$NDXP 20250220 21930.0 PUT$ not too shabby...","images":[{"img":"https://community-static.tradeup.com/news/dfa726d12b30d7f1e35c8d730400e6e0","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/405735852032120","isVote":1,"tweetType":1,"viewCount":2944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":400114343837816,"gmtCreate":1738709284036,"gmtModify":1738709287860,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250204 21680.0 CALL\">$NDXP 20250204 21680.0 CALL$ </a> be brave..","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250204 21680.0 CALL\">$NDXP 20250204 21680.0 CALL$ </a> be brave..","text":"$NDXP 20250204 21680.0 CALL$ be brave..","images":[{"img":"https://community-static.tradeup.com/news/f79509fd267a5846f2a5e7c2c3d138b3","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":3,"link":"https://ttm.financial/post/400114343837816","isVote":1,"tweetType":1,"viewCount":2811,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3559581955535845","idStr":"3559581955535845"},"content":"Congratulations on your winning trade 😍😍😍🎊🎊🎊","text":"Congratulations on your winning trade 😍😍😍🎊🎊🎊","html":"Congratulations on your winning trade 😍😍😍🎊🎊🎊"},{"author":{"id":"4200461089366592","authorId":"4200461089366592","name":"BryanMing","avatar":"https://community-static.tradeup.com/news/a3e7d6a0b525d91e56281f84bc4ab276","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"4200461089366592","idStr":"4200461089366592"},"content":"//@Barcode:🔥🔥🔥 AWESOME fire fire fire! 🔥🔥🔥","text":"//@Barcode:🔥🔥🔥 AWESOME fire fire fire! 🔥🔥🔥","html":"//@Barcode:🔥🔥🔥 AWESOME fire fire fire! 🔥🔥🔥"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":400113784180952,"gmtCreate":1738709161644,"gmtModify":1738709165731,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250204 21580.0 CALL\">$NDXP 20250204 21580.0 CALL$ </a> not too shabby","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250204 21580.0 CALL\">$NDXP 20250204 21580.0 CALL$ </a> not too shabby","text":"$NDXP 20250204 21580.0 CALL$ not too shabby","images":[{"img":"https://community-static.tradeup.com/news/255b18613486b42a30efdb1fd1309d0e","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/400113784180952","isVote":1,"tweetType":1,"viewCount":3308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":398695864640040,"gmtCreate":1738363165884,"gmtModify":1738369199881,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250131 21850.0 CALL\">$NDXP 20250131 21850.0 CALL$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250131 21850.0 CALL\">$NDXP 20250131 21850.0 CALL$ </a>&nbsp;","text":"$NDXP 20250131 21850.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/7832919cec740f54e80972b3b6288038","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/398695864640040","isVote":1,"tweetType":1,"viewCount":2762,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":397920080503304,"gmtCreate":1738188783096,"gmtModify":1738192093707,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250129 21580.0 CALL\">$NDXP 20250129 21580.0 CALL$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250129 21580.0 CALL\">$NDXP 20250129 21580.0 CALL$ </a>&nbsp;","text":"$NDXP 20250129 21580.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/0f4c866fcbd4926716ce64153a4c388c","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/397920080503304","isVote":1,"tweetType":1,"viewCount":3137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":397982209642712,"gmtCreate":1738188757704,"gmtModify":1738188761811,"author":{"id":"3570742778586711","authorId":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570742778586711","idStr":"3570742778586711"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NDXP 20250129 21580.0 CALL\">$NDXP 20250129 21580.0 CALL$ </a> collected Lasser from the north side but still is&nbsp; a good shot..","listText":"<a href=\"https://ttm.financial/OPT/NDXP 20250129 21580.0 CALL\">$NDXP 20250129 21580.0 CALL$ </a> collected Lasser from the north side but still is&nbsp; a good shot..","text":"$NDXP 20250129 21580.0 CALL$ collected Lasser from the north side but still is a good shot..","images":[{"img":"https://community-static.tradeup.com/news/51676b44617d197edb96aa84cdc4b408","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/397982209642712","isVote":1,"tweetType":1,"viewCount":2754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}